A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLECT Study)

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study ID
NCT06195111
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trifluridine/Tipiracil — DRUG
    This a rospective observational study. There is no treatment allocation. Patients administered Trifluridine/Tipiracil by prescription

Study Details

A real-world study of trifluridine/tipiracil containing regimen for the treatment of patients with metastatic colorectal cancer. A total of 200 patients planned to be enrolled.

Key Dates

First listed
Jan 8, 2024
Start date
Mar 1, 2024
Status verified
Dec 2023
Primary completion
Mar 1, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Trifluridine/Tipiracil
    Patients with metastatic colorectal cancer plan to recieve Trifluridine/Tipiracil-containing treatment will be enrolled in this study. The prescription all determined by doctor based on patient's situation.

Primary Outcome Measure

PFS (Progression-free survival) [ Time Frame: Approximately 12 months ]

Central Contacts

Related Studies